Skip to main content
    B

    Barinthus Biotherapeutics plc (BRNS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • PINK

    $0.74
    +0.00 (+0.00%)

    Market Cap: $30.23M

    Last updated: Nov 13, 2026 at 4:00 PM ET

    Barinthus Biotherapeutics plc (BRNS) Financials: Revenue, Profit and Cash Flow

    Updated Aug 6, 2026. Financial statements from company filings, amounts in US dollars.

    Barinthus Biotherapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025, down 100.0% from the year before. That year, net income was -$66.58M, operating cash flow was -$47.98M and free cash flow was -$48.02M. The quarter ended Jun 30, 2026 had revenue of $0 and net income of -$10.58M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $54.19M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0-100.0%N/AN/AN/A
    Dec 2024$14.97M+1766.5%100.0%-454.1%-408.0%
    Dec 2023$802.00K-98.2%100.0%-10463.1%-9145.5%
    Dec 2022$44.70M+16580.2%100.0%-9.0%11.9%
    Dec 2021$268.00K-94.4%100.0%-16873.5%-18979.5%
    Dec 2020$4.82M-29.6%-198.4%-415.8%-367.3%
    Dec 2019$6.85MN/A-336.0%-374.9%-302.8%
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$0$14.97M$802.00K$44.70M$268.00K$4.82M$6.85M
    Cost of revenue$5.86M$5.80M$3.11KN/AN/A$14.39M$29.84M
    Gross profit-$5.86M$14.97M$802.00K$44.70M$268.00K-$9.57M-$23.00M
    Research and development$25.56M$38.25M$41.41M$41.11M$16.37M$14.39M$29.84M
    Operating income-$54.19M-$67.97M-$83.91M-$4.04M-$45.22M-$20.05M-$25.66M
    Net income-$66.58M-$61.07M-$73.35M$5.34M-$50.87M-$17.71M-$20.73M
    EBITDAN/A-$55.37M-$71.06M$5.19MN/A-$16.56M-$22.34M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$0$0$0$0$0$0-$9.17M$14.97M$0$0$5.37M$0
    Gross profitN/A-$854.57K-$907.69KN/A-$2.02M-$2.04M-$69.00K$14.97M-$1.47M-$1.43M$3.92M-$1.47M
    Operating income-$11.02M-$9.11M-$9.41M-$15.07M-$23.32M-$20.60M-$23.39M-$9.38M-$18.29M-$16.91M-$19.99M-$16.11M
    Net income-$10.58M-$5.52M-$11.07M-$14.57M-$21.12M-$19.65M-$20.54M-$8.11M-$16.93M-$15.49M-$17.29M-$14.07M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $2.02M by $68.43M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$98.17M$160.33M$214.51M$270.20M$280.71M$50.67M$19.04M
    Current assets$77.79M$125.74M$156.91M$213.04M$226.76M$47.90M$16.25M
    Cash and equivalents$70.46M$110.66M$142.09M$194.38M$214.05M$43.27M$11.43M
    Total liabilities$23.88M$30.19M$27.51M$27.00M$28.15M$53.81M$41.12M
    Short-term debt$2.02M$1.92M$1.78M$433.00K$682.00K$192.00K$171.98K
    Long-term debtN/AN/AN/AN/AN/A$44.70MN/A
    Shareholder equity$74.21M$130.03M$186.78M$242.90M$252.13M-$3.54M-$22.45M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$81.89M$92.14M$98.17M$109.20M$129.56M$142.00M$160.33M$188.69M$186.75M$199.48M$214.51M$229.97M
    Total liabilities$24.76M$25.66M$23.88M$24.64M$27.08M$26.40M$30.19M$29.23M$29.96M$27.47M$27.51M$34.37M
    Cash and equivalents$59.30M$67.19M$70.46M$74.27M$86.26M$99.12M$110.66M$106.10M$117.77M$129.97M$142.09M$160.31M
    Shareholder equity$57.07M$66.40M$74.21M$84.47M$102.38M$115.49M$130.03M$159.29M$156.62M$171.83M$186.78M$195.40M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$47.98M-$28.94M-$50.92M-$14.43M-$32.58M-$11.03M-$18.76M
    Capital expenditures$37.00K$892.00K$5.41M$6.14M$1.15M$293.00K$128.35K
    Free cash flow-$48.02M-$29.83M-$56.34M-$20.57M-$33.73M-$11.32M-$18.89M
    Investing cash flow$416.00K-$892.00K-$5.41M-$5.75M-$12.91M-$293.00K$1.93M
    Financing cash flow$2.00K$2.16M$1.87M$325.00K$222.74M$41.44M$1
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$8.09M-$3.37M-$4.24M-$10.73M-$18.11M-$14.90M$13.09M-$18.20M-$12.01M-$11.82M-$19.60M-$11.19M
    Capital expenditures$0$2$50$182$32.00K$5.00K$278.00K$114.00K$192.00K$308.00K$153.00K$36.00K
    Free cash flow-$8.09M-$3.37M-$4.24M-$10.73M-$18.14M-$14.91M$12.81M-$18.31M-$12.20M-$12.13M-$19.76M-$11.23M
    Last 12 quarters

    Frequently Asked Questions About BRNS

    What is Barinthus Biotherapeutics' annual revenue?

    Barinthus Biotherapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    How fast is Barinthus Biotherapeutics' revenue growing?

    Revenue was down 100.0% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Barinthus Biotherapeutics profitable?

    No. Barinthus Biotherapeutics reported net income of -$66.58M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does BRNS generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$47.98M minus capital expenditures of $37.00K produced free cash flow of -$48.02M.

    How much debt does Barinthus Biotherapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $2.02M and cash and equivalents of $70.46M.